Why Nanobiotech Pharma?

• We are the pioneers of CNP/Nanobacteria R&D and developed the first & only nanobiotics. We are the only Company with effective nanobiotic therapies shown in clinical studies to treat CNP/Nanobacteria infections, reverse pathological calcification, inflammation and the attendant plaque effects in multiple diseases. Our researchers were the scientists that discovered CNP/Nanobacteria and and developed the diagnostics for CNP/Nanobacteria Antibodies & Antigen. 

• We know CNP/Nanobacteria and the idiosyncrasies/effects better than anyone else. CNP/Nanobacteria have been shown to be the cause of pathological calcification (disease-related) calcium deposits) in heart disease, arthritis, kidney disease, neurodegenerative diseases, dermatological diseases and other chronic disorders as have been published in many leading scientific/medical journals. Until studies by Mezo & Kajander, no previous research had shown the cause of pathological calcification. No process or organism has otherwise been found that produces these rock-hard calcified deposits under normal serum & blood conditions, except CNP/Nanobacteria.

Clearly, since we developed the market, we have an advantage.

• Nanobiotech Pharma has a range of Nanobiotic compounds, NanobacTX, Urobac, Dermabac and others that consist of well known and GRAS (safe) ingredients that have been shown to convincingly eradicate nanobacteria in vitro and in vivo as published by the US Patent Office.

• Nanobiotech Pharma has license to an extensive, niche-encompassing and compelling family of related intellectual property, including proprietary diagnostics that can recognize CNP/nanobacteria in serum, blood, urine and human tissue. Recently, these diagnostics have shown that nanobacteria bind disease-causing proteins in uniquely identifiable combinations, opening new doors to the early diagnosis and differentiation of many diseases.

• Published clinical and/or scientific studies have shown that our nanobiotics are effective at treating heart disease, arteriosclerosis, atherosclerosis, BPH and prostatitis where no other treatments have previously succeeded. From our studies, we have learned valuable information about compliance, drug effectiveness, safety and the mechanisms of action of our nanobiotics. No serious safety problems have been encountered.

• Our pipeline of new therapeutics in development is one of the most unique and encompassing in the industry, focusing exclusively on curative therapies for a broad range of unmet medical needs. Unlike most, we seek to discover and develop cures,  rather than palliative treatment of symptoms. Relying on the strength of our pipeline and scientific talent, we continue to generate a steady stream of breakthroughs. Our researchers continue to work around the clock and around the globe.